In Q4 2025, Perceptive Advisors held 101 positions worth $5.2B. They initiated 20 new positions and exited 101. Their largest holding was PRAX ($588.3M). Portfolio value grew +62.0% versus the prior quarter.
Frequently asked questions
What stocks did Perceptive Advisors own in Q4 2025?
Perceptive Advisors held 101 biotech stocks in their 13F portfolio in Q4 2025. Their top positions include PRAX, CELC, RYTM, ASND, APGE. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Perceptive Advisors's portfolio worth in Q4 2025?
Perceptive Advisors's tracked biotech portfolio was worth $5.2B across 101 positions, with total assets under management of approximately $8B. Portfolio values are based on 13F filings with the SEC.
What did Perceptive Advisors buy in Q4 2025?
Perceptive Advisors initiated 20 new positions in Q4 2025, including IVVD, JAZZ, PALI, BCRX, BIIB and 15 more. They also increased 41 existing positions.
What did Perceptive Advisors sell in Q4 2025?
Perceptive Advisors fully exited 101 positions in Q4 2025, including HLXC, GMED, VERU, TARS, MDT and 96 more. They also trimmed 18 existing positions.
Is Perceptive Advisors a biotech fund?
Clinical-stage biotech specialist known for deep scientific due diligence and concentrated bets on binary catalysts like FDA approvals and pivotal trial readouts. Edelman and team leverage decades of pattern recognition in drug development to identify asymmetric risk/reward setups.
Want AI analysis, insider signals, and catalyst overlays for Perceptive Advisors?
View latest Perceptive Advisorsportfolio →